Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy
Phase 4
- Conditions
- Myomectomy
- Interventions
- Registration Number
- NCT04357015
- Lead Sponsor
- Cairo University
- Brief Summary
the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 153
Inclusion Criteria
- women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging
Exclusion Criteria
- women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intravenous tranexamic acid intravenous tranexamic acid The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision intravenous carbetocin intravenous carbetocin The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision placebo placebo the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
- Primary Outcome Measures
Name Time Method intraoperative blood loss one hour the intraoperative blood loss in ml will be estimated during the procedure
- Secondary Outcome Measures
Name Time Method need for blood transfusion 24 hours need for intraoperative or postoperative blood transfusion